CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
两种共刺激优于一种：内源性 CD28 在 4-1BB CAR-T 细胞中的作用
英文原题：Two Costimulations Are Better Than One: Role of Endogenous CD28 in 4-1BB CAR T Cells.
查看英文原题
Two Costimulations Are Better Than One: Role of Endogenous CD28 in 4-1BB CAR T Cells.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
Liberman及其同事发现，内源性CD28信号通过促进代谢适应性、增殖和持续的抗肿瘤功能，成为4-1BB嵌合抗原受体（CAR）T细胞功能的调节因子。这些发现强调了CD28和4-1BB信号的协同整合，以发挥CAR-T 细胞的效力、持久性和治疗效果。参见Lieberman等人第441页的相关文章。
展开英文摘要原文
Liberman and colleagues identify endogenous CD28 signaling as a regulator of 4-1BB chimeric antigen receptor (CAR) T-cell function by promoting metabolic fitness, proliferation, and sustained antitumor function.
These findings highlight the cooperative integration of CD28 and 4-1BB signaling to harness CAR T-cell potency, persistence, and therapeutic efficacy. See related article by Lieberman et al. , p. 441.
论文信息
- 作者
- Hamieh M、Sadelain M
- 第一作者单位
- Department of Pediatrics, Meyer Cancer Center, Drukier Institute for Children's Health, Parker Institute for Cancer Immunotherapy, Weill Cornell Medicine, New York, New York.United States
- 通讯作者单位
- Columbia Initiative in Cell Engineering and Therapy (CICET), Vagelos College of Physicians and Surgeons, Columbia University Irving Medical Center, New York, New York.United States
- 期刊
- Blood cancer discovery2026 May 5
- 原文标识
- PubMed 41848361 · DOI 10.1158/2643-3230.BCD-25-0491